ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.
Equities
IPA
CA45257F2008
Pharmaceuticals
Sales 2024 * | 24.59M 17.87M | Sales 2025 * | 29.82M 21.68M | Capitalization | 44.86M 32.61M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.72M | Net income 2025 * | -9M -6.54M | EV / Sales 2024 * | 1.82 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.5 x |
P/E ratio 2024 * |
-3.53
x | P/E ratio 2025 * |
-4.79
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
-5.99% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+50.82% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-3.75% | 8.07B |